OLIG2_HUMAN
ID OLIG2_HUMAN Reviewed; 323 AA.
AC Q13516; B3KRF3; Q05BP9; Q49AL3; Q86X04; Q9NZ14;
DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT 13-AUG-2002, sequence version 2.
DT 03-AUG-2022, entry version 174.
DE RecName: Full=Oligodendrocyte transcription factor 2;
DE Short=Oligo2;
DE AltName: Full=Class B basic helix-loop-helix protein 1;
DE Short=bHLHb1;
DE AltName: Full=Class E basic helix-loop-helix protein 19;
DE Short=bHLHe19;
DE AltName: Full=Protein kinase C-binding protein 2;
DE AltName: Full=Protein kinase C-binding protein RACK17;
GN Name=OLIG2; Synonyms=BHLHB1, BHLHE19, PRKCBP2, RACK17;
OS Homo sapiens (Human).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC Homo.
OX NCBI_TaxID=9606;
RN [1]
RP NUCLEOTIDE SEQUENCE [MRNA].
RC TISSUE=Hippocampus;
RA Kuroda S., Tokunaga C., Kiyohara Y., Konishi H., Kikkawa U.;
RT "Protein kinase C-binding protein.";
RL Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases.
RN [2]
RP NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION.
RX PubMed=10737801; DOI=10.1073/pnas.97.7.3497;
RA Wang J., Jani-Sait S.N., Escalon E.A., Carroll A.J., de Jong P.J.,
RA Kirsch I.R., Aplan P.D.;
RT "The t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell
RT acute lymphoblastic leukemia activates the BHLHB1 gene.";
RL Proc. Natl. Acad. Sci. U.S.A. 97:3497-3502(2000).
RN [3]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Brain;
RX PubMed=14702039; DOI=10.1038/ng1285;
RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA Isogai T., Sugano S.;
RT "Complete sequencing and characterization of 21,243 full-length human
RT cDNAs.";
RL Nat. Genet. 36:40-45(2004).
RN [4]
RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC TISSUE=Brain;
RX PubMed=15489334; DOI=10.1101/gr.2596504;
RG The MGC Project Team;
RT "The status, quality, and expansion of the NIH full-length cDNA project:
RT the Mammalian Gene Collection (MGC).";
RL Genome Res. 14:2121-2127(2004).
RN [5]
RP TISSUE SPECIFICITY.
RX PubMed=11498220; DOI=10.1016/s0140-6736(01)05499-x;
RA Marie Y., Sanson M., Mokhtari K., Leuraud P., Kujas M., Delattre J.-Y.,
RA Poirier J., Zalc B., Hoang-Xuan K.;
RT "OLIG2 as a specific marker of oligodendroglial tumour cells.";
RL Lancet 358:298-300(2001).
RN [6]
RP TISSUE SPECIFICITY.
RX PubMed=11526205; DOI=10.1073/pnas.181340798;
RA Lu Q.R., Park J.K., Noll E., Chan J.A., Alberta J.A., Yuk D.-I.,
RA Alzamora M.G., Louis D.N., Stiles C.D., Rowitch D.H., Black P.M.;
RT "Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial
RT brain tumors.";
RL Proc. Natl. Acad. Sci. U.S.A. 98:10851-10856(2001).
CC -!- FUNCTION: Required for oligodendrocyte and motor neuron specification
CC in the spinal cord, as well as for the development of somatic motor
CC neurons in the hindbrain. Functions together with ZNF488 to promote
CC oligodendrocyte differentiation. Cooperates with OLIG1 to establish the
CC pMN domain of the embryonic neural tube. Antagonist of V2 interneuron
CC and of NKX2-2-induced V3 interneuron development.
CC {ECO:0000250|UniProtKB:Q9EQW6}.
CC -!- SUBUNIT: Interacts with NKX2-2. Interacts with ZNF488.
CC {ECO:0000250|UniProtKB:Q9EQW6}.
CC -!- INTERACTION:
CC Q13516; P60329: KRTAP12-4; NbExp=3; IntAct=EBI-3914525, EBI-10176396;
CC Q13516; P40222: TXLNA; NbExp=3; IntAct=EBI-3914525, EBI-359793;
CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00981}.
CC Cytoplasm {ECO:0000250}. Note=The NLS contained in the bHLH domain
CC could be masked in the native form and translocation to the nucleus
CC could be mediated by interaction either with class E bHLH partner
CC protein or with NKX2-2. {ECO:0000250}.
CC -!- TISSUE SPECIFICITY: Expressed in the brain, in oligodendrocytes.
CC Strongly expressed in oligodendrogliomas, while expression is weak to
CC moderate in astrocytomas. Expression in glioblastomas highly variable.
CC {ECO:0000269|PubMed:11498220, ECO:0000269|PubMed:11526205}.
CC -!- INDUCTION: By SHH. Also induced by NKX6-1 in the developing spinal
CC cord, but not in the rostral hindbrain (By similarity). {ECO:0000250}.
CC -!- DOMAIN: The bHLH is essential for interaction with NKX2-2.
CC {ECO:0000250}.
CC -!- DISEASE: Note=A chromosomal aberration involving OLIG2 may be a cause
CC of a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation
CC t(14;21)(q11.2;q22) with TCRA. {ECO:0000269|PubMed:10737801}.
CC -!- SEQUENCE CAUTION:
CC Sequence=AAC72247.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC Sequence=AAF61215.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC Haematology;
CC URL="http://atlasgeneticsoncology.org/Genes/OLIG2ID236.html";
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; U48250; AAC72247.1; ALT_INIT; mRNA.
DR EMBL; AF221520; AAF61215.1; ALT_INIT; mRNA.
DR EMBL; AK091462; BAG52365.1; -; mRNA.
DR EMBL; BC034681; AAH34681.1; -; mRNA.
DR EMBL; BC036245; AAH36245.1; -; mRNA.
DR EMBL; BC047511; AAH47511.1; -; mRNA.
DR CCDS; CCDS13620.1; -.
DR PIR; G02409; G02409.
DR RefSeq; NP_005797.1; NM_005806.3.
DR RefSeq; XP_005260965.1; XM_005260908.1.
DR AlphaFoldDB; Q13516; -.
DR SMR; Q13516; -.
DR BioGRID; 115510; 10.
DR IntAct; Q13516; 3.
DR STRING; 9606.ENSP00000331040; -.
DR iPTMnet; Q13516; -.
DR PhosphoSitePlus; Q13516; -.
DR BioMuta; OLIG2; -.
DR DMDM; 22261817; -.
DR MassIVE; Q13516; -.
DR PaxDb; Q13516; -.
DR PeptideAtlas; Q13516; -.
DR PRIDE; Q13516; -.
DR Antibodypedia; 917; 495 antibodies from 41 providers.
DR DNASU; 10215; -.
DR Ensembl; ENST00000333337.3; ENSP00000331040.3; ENSG00000205927.5.
DR Ensembl; ENST00000382357.4; ENSP00000371794.3; ENSG00000205927.5.
DR GeneID; 10215; -.
DR KEGG; hsa:10215; -.
DR MANE-Select; ENST00000382357.4; ENSP00000371794.3; NM_005806.4; NP_005797.1.
DR UCSC; uc002yqx.3; human.
DR CTD; 10215; -.
DR DisGeNET; 10215; -.
DR GeneCards; OLIG2; -.
DR HGNC; HGNC:9398; OLIG2.
DR HPA; ENSG00000205927; Group enriched (brain, choroid plexus).
DR MIM; 606386; gene.
DR neXtProt; NX_Q13516; -.
DR OpenTargets; ENSG00000205927; -.
DR PharmGKB; PA31919; -.
DR VEuPathDB; HostDB:ENSG00000205927; -.
DR eggNOG; KOG3898; Eukaryota.
DR GeneTree; ENSGT00940000161651; -.
DR HOGENOM; CLU_065376_1_0_1; -.
DR InParanoid; Q13516; -.
DR OMA; PVHHPIL; -.
DR OrthoDB; 1290623at2759; -.
DR PhylomeDB; Q13516; -.
DR TreeFam; TF322733; -.
DR PathwayCommons; Q13516; -.
DR SignaLink; Q13516; -.
DR SIGNOR; Q13516; -.
DR BioGRID-ORCS; 10215; 18 hits in 1093 CRISPR screens.
DR GeneWiki; OLIG2; -.
DR GenomeRNAi; 10215; -.
DR Pharos; Q13516; Tbio.
DR PRO; PR:Q13516; -.
DR Proteomes; UP000005640; Chromosome 21.
DR RNAct; Q13516; protein.
DR Bgee; ENSG00000205927; Expressed in inferior vagus X ganglion and 76 other tissues.
DR ExpressionAtlas; Q13516; baseline and differential.
DR Genevisible; Q13516; HS.
DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR GO; GO:0071837; F:HMG box domain binding; IEA:Ensembl.
DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl.
DR GO; GO:0046983; F:protein dimerization activity; IEA:InterPro.
DR GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL.
DR GO; GO:0042552; P:myelination; IEA:Ensembl.
DR GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl.
DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl.
DR GO; GO:0030182; P:neuron differentiation; IBA:GO_Central.
DR GO; GO:0048663; P:neuron fate commitment; IEA:Ensembl.
DR GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl.
DR GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR GO; GO:0021522; P:spinal cord motor neuron differentiation; IEA:Ensembl.
DR GO; GO:0021530; P:spinal cord oligodendrocyte cell fate specification; IEA:Ensembl.
DR GO; GO:0021794; P:thalamus development; IEA:Ensembl.
DR Gene3D; 4.10.280.10; -; 1.
DR InterPro; IPR011598; bHLH_dom.
DR InterPro; IPR036638; HLH_DNA-bd_sf.
DR InterPro; IPR032658; Olig2.
DR PANTHER; PTHR19290:SF32; PTHR19290:SF32; 1.
DR Pfam; PF00010; HLH; 1.
DR SMART; SM00353; HLH; 1.
DR SUPFAM; SSF47459; SSF47459; 1.
DR PROSITE; PS50888; BHLH; 1.
PE 1: Evidence at protein level;
KW Chromosomal rearrangement; Cytoplasm; Developmental protein; DNA-binding;
KW Nucleus; Proto-oncogene; Reference proteome; Transcription;
KW Transcription regulation.
FT CHAIN 1..323
FT /note="Oligodendrocyte transcription factor 2"
FT /id="PRO_0000127414"
FT DOMAIN 108..162
FT /note="bHLH"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00981"
FT REGION 1..107
FT /note="Disordered"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 28..48
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT COMPBIAS 73..95
FT /note="Polar residues"
FT /evidence="ECO:0000256|SAM:MobiDB-lite"
FT CONFLICT 67
FT /note="G -> V (in Ref. 3; AAH36245)"
FT /evidence="ECO:0000305"
FT CONFLICT 150
FT /note="A -> T (in Ref. 4; AAH47511)"
FT /evidence="ECO:0000305"
SQ SEQUENCE 323 AA; 32385 MW; 0EC9223961062509 CRC64;
MDSDASLVSS RPSSPEPDDL FLPARSKGSS GSAFTGGTVS SSTPSDCPPE LSAELRGAMG
SAGAHPGDKL GGSGFKSSSS STSSSTSSAA ASSTKKDKKQ MTEPELQQLR LKINSRERKR
MHDLNIAMDG LREVMPYAHG PSVRKLSKIA TLLLARNYIL MLTNSLEEMK RLVSEIYGGH
HAGFHPSACG GLAHSAPLPA ATAHPAAAAH AAHHPAVHHP ILPPAAAAAA AAAAAAAVSS
ASLPGSGLPS VGSIRPPHGL LKSPSAAAAA PLGGGGGGSG ASGGFQHWGG MPCPCSMCQV
PPPHHHVSAM GAGSLPRLTS DAK
